GMED · NASDAQ · STOCK
Globus Medical
$83.24
52W $54.15 – $101.40
71/100
$11.11B
20.7
0.95
Is GMED Bullish or Bearish?
Bullish.
Innellis AI committee rates Globus Medical (GMED) Buy with a composite score of 71/100
, based on 4 analysts with 100% agreement.
Last updated August 09, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +4.48 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -15.52 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.33 across 21 articles, 14d) — News
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 09, 2026
Overall Committee Score
71/100
Agreement
100%
Analysts
4
Conviction
Unanimous
Sector Rank
Top 4%
of 95 Healthcare peers
Growth Analyst
bullish
82
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 21 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 70.0 to 70.5.
- Bullish support removed: 2 signal(s) disappeared.
- Analyst(s) abstained: Risk Analyst, Value Analyst.
Analyst-level changes:
- Growth Analyst: score 79->82 (+4).
- Risk Analyst abstained (was bullish at 80).
- Value Analyst abstained (was bullish at 62).
Comparing 2026-08-08 to 2026-08-09 (1 day apart).
Technical Analysis
RSI (14)
64.2
Neutral
MACD Histogram
0.532
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$82.10
Resistance
$83.83
Bollinger %B
0.86
Inside Bands
Price vs Moving Averages
EMA 9
$80.61
Above
EMA 21
$79.71
Above
EMA 50
$80.31
Above
EMA 200
$80.90
Above
Fundamental Analysis
Valuation
88
Growth
85
Profitability
86
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
20.7×
P/B Ratio
2.34×
PEG Ratio
0.40
Dividend Yield
0.00%
52W High
$101.40
52W Low
$54.15
Quality & Growth
ROE
1176.2%
ROA
1014.4%
Gross Margin
6854.8%
Operating Margin
2075.4%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
P/E ratio of 20.7 (inexpensive relative to a 15-40x range); Price-to-book of 2.3x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.8%; Return on assets of 10.1%; Net margin of 17.0%; Gross margin of 68.5%; Current ratio of 4.62 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is positive (6.75); Most recent quarter beat estimates by 19.5%; 5 consecutive earnings beats; EPS growth accelerating (-12.5% -> +19.6% QoQ); Average YoY EPS growth of 55.8%; Analyst estimates falling over recent quarters
Get the Full GMED Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →